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63:1009–10.REPLY: A Commentary on the SPARC StudyWe appreciate the interest of Drs. Lundbye and
Heller in our paper (1). They are concerned about the
selection of patients for computed tomography angi-
ography, positron emission tomography, and single-
photon emission computed tomography, because
there were many differences in the baseline charac-
teristics of these groups. The baseline characteristics
listed in Table 1 of our paper are for the entire
study population, not the propensity score–matched
patients used to compare the outcomes. The charac-
teristics of the matched patients (Table 3 in our
paper) are quite similar. Although propensity score
matching may not fully adjust for patient selection,
it largely corrects for the imbalances in baseline
characteristics.*Mark Hlatky, MD
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Again Results in Better
Patient OutcomesThe SPARC (Study of Myocardial Perfusion and Coro-
nary Anatomy Imaging Roles in Coronary Artery
Disease) Study by Hlatky et al. (1) is the latest of mul-
tiple studies showing improved outcomes with use of
computed tomography angiography (CTA). Although
this may not be surprising, because neither single-
photon emission computed tomography (SPECT) nor
positron emission tomography can detect subclinical
atherosclerosis, it is understated in the current paper.
The 2-year event rate for nonfatal myocardial infarc-
tion (MI) and death, a standard hard endpoint for
many studies, was 1% (6 of 590) for CTA, 2.8% (16 of
565) for SPECT, and 6.6% (36 of 548) for positron
emission tomography (p < 0.001), favoring CTA. This
was meaningful in absolute terms as well, represent-
ing a number needed to scan of only 55 for CTA
over SPECT and 18 for CTA over positron emission
tomography to prevent one MI or death. The cost-
effectiveness per life year saved was also quite low at
$10,700 per life year added. Furthermore, the median
(interquartile range) cost of care for CTA and SPECT
was virtually identical at $2,820 ($1,777 to $4,585) for
CTA and $2,810 ($1,692 to $4,436) for SPECT.
The results of SPARC are highly concurrent with a
much larger observation by Shreibati et al. (2). They
demonstrated that compared with stress myocardial
perfusion imaging, coronary CTAwas associatedwith a
40% reduction (odds ratio: 0.60; 95% conﬁdence
interval [CI]: 0.37 to 0.98; p ¼ 0.04) in acute MI after
multivariable adjustment. The study, which was
limited to 180 days of follow-up, included 8,820
patients undergoing CTA and 132,343 patients under-
going myocardial perfusion imaging. Despite the short
follow-up period, an 18% (nonsigniﬁcant) reduction in
all-cause mortality (1.05% for CTA vs. 1.28% for myo-
cardial perfusion imaging; p ¼ 0.32) was also shown.
This beneﬁt of CTA as compared with functional
testing was evaluated in a meta-analysis of CTA and
functional testing for diagnosis and outcomes (3). The
combined results of 11 studies including 1,575 patients
showed a higher diagnostic sensitivity for CTA versus
exercise electrocardiography and SPECT (98% [95%
CI: 93% to 99%] vs. 67% [95% CI: 54% to 78%] [p <
0.001] and 99% [95% CI: 96% to 100%] vs. 73% [95%
CI: 59% to 83%] [p ¼ 0.001], respectively). The spec-
iﬁcity of CTA was 82% (95% CI: 63% to 93%) versus
46% (95% CI: 30% to 64%) (p < 0.001) for exercise
